CN104224962A - 一种治疗间质性膀胱炎的中药组合物 - Google Patents
一种治疗间质性膀胱炎的中药组合物 Download PDFInfo
- Publication number
- CN104224962A CN104224962A CN201410434817.XA CN201410434817A CN104224962A CN 104224962 A CN104224962 A CN 104224962A CN 201410434817 A CN201410434817 A CN 201410434817A CN 104224962 A CN104224962 A CN 104224962A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- interstitial cystitis
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000005615 Interstitial Cystitis Diseases 0.000 title claims abstract description 17
- 239000002994 raw material Substances 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 18
- 230000008901 benefit Effects 0.000 abstract description 3
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 244000130463 Alangium chinense Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010052315 Lymphatic obstruction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪5-20份,附子2-10份,当归5-15份,苦参5-10份,白芍5-15份,甘草3-10份,八角枫根5-15份。本发明对于间质性膀胱炎的治疗具有疗效好、安全性较高、治疗费用低廉,值得临床应用、推广等优点。
Description
技术领域:
本发明涉及中医药技术领域,特别涉及一种治疗间质性膀胱炎的中药组合物。
背景技术:
间质性膀胱炎患者的个体症状差异较大,即使在同一患者,也可出现不同的症状。患者可以有膀胱和盆腔周围的轻度不适、压迫感、压痛,或剧烈疼痛。症状可能包括急迫排 尿(尿急),频繁排尿(尿频),或者这些同时存在。在膀胱充满尿液时这些症状会加重,也可能在空虚时加重。
由于患者尿液检查均正常,感染并非膀胱壁纤维化的主要病因,有学者认为盆腔外科手术或感染产生的淋巴管梗阻是其病因,而许多患者没有这样的病史。亦有学者提出是由于血栓静脉炎伴膀胱或骨盆内脏器急性感染,或由于精神冲动产生长期小动脉的痉挛所致,还可能与内分泌因素有关。目前,大量的证据认为间质性膀胱炎是一种自体免疫胶原性疾病,所以目前还没有较好的治疗药物。
发明内容:
本发明就是为了克服现有技术中的不足提供一种对于间质性膀胱炎的治疗具有疗效明显,无不良反应,成方简单,治疗费用低廉的中药组合物。
本发明提供以下技术方案:
一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪5-20份,附子2-10份,当归5-15份,苦参5-10份,白芍5-15份,甘草3-10份,八角枫根5-15份。
配方优选为:
黄芪12份,附子3份,当归10份,苦参5份,白芍10份,甘草5份,八角枫根10份。
制备与服用方法:
按上述中药配方中重量组份取各种原料,使用传统的中药制备方法,煎煮数次,合并煎煮液,分早中晚三次服用,连服一周为一个疗程。
组成本发明的各中药原料的详细说明如下:
黄芪:味甘,性微温。归肺、脾、肝、肾经。具有益气固表、敛汗固脱、托疮生肌、利水消肿等功效。常用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等症。本品有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。能消除实验性肾炎蛋白尿,增强心肌收缩力,调节血糖含量。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。
附子:味辛、甘,性大热;有毒。归心、肾、脾经。具有回阳救逆,补火助阳,逐风寒湿邪等功效。常用于亡阳虚脱,肢冷脉微,阳萎,宫冷,心腹冷痛,虚寒吐泻,阴寒水肿,阳虚外感,寒湿痹痛等症。研究表明:附子能增强心肌收缩力,加快心率,增加心输出量,增加心肌耗氧量;附子有扩张血管,增加血流,改善血液循环作用;附子对血压的影响既有升压又有降压作用,与其所含成分有关;附子回阳救这之功效主要是以强心抗休克作用为基础;附子有显著的抗缓慢型心律失常作用;附子煎剂对急性炎症模型有明显抑制作用。
当归:味甘、辛,性温。归肝、心、脾经。具有补血活血,调经止痛,润肠通便等功效。常用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,肠燥便秘,风湿痹痛,跌扑损伤,痈疽疮疡等症。本品还具有抗血栓;改善血液循环;对心律失常具有保护作用;显著增加冠脉流量,降低冠脉阻力和心肌耗氧量,增加心排出量和心搏指数,减轻阻断冠脉时的心肌梗死范围;扩张血管;抗炎;镇痛;降血糖;保肝;利胆;当归多糖可通过直接和间接途径激活造血微环境中的巨噬细胞、淋巴细胞等,也可刺激肌组织,促进其产生造血调控因子,进而促进功能造血干细胞粒细胞巨噬细胞集落成单位的增殖分化,刺激骨髓粒单系造血;当归对体外痢疾、伤寒、副伤寒、大肠杆菌、白喉杆菌、霍乱弧菌及a、B溶血性链球菌等均有抗菌作用,此外还可以创面愈合,使局部充血、白细胞和纤维浸润,新生上皮再生,对局部组织有止血和加强末梢循环作用;当归对动物和人离体细胞内2、3-二磷酸生成有促进作用,降低血红蛋白与氧的亲和力,促进带氧血红蛋白在组织中释放氧,从而增加了红细胞运输氧的功能。
苦参:味苦,性寒。归心、肝、胃、大肠、膀胱经。具有清热燥湿,杀虫,利尿等功效。常用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治滴虫性阴道炎等症。本品还具有利尿、抗病原体、抗肿瘤、提升白细胞、扩张血管、降压、镇静、抗过敏、促进受损血管神经细胞的生长和修复,恢复皮下毛细血管细胞活力,肌肤重现紧致细滑,起到美容护肤等作用。
白芍:味苦、酸,性微寒。归肝、脾经。具有平肝止痛,养血调经,敛阴止汗等功效。常用于头痛眩晕,胁痛,腹痛,四肢挛痛,血虚萎黄,月经不调,自汗,盗汗等症。本品扩张冠状动脉,降低血压,d-儿茶精和没食子酸乙酯有抗血栓和抗血小板聚集作用;所致肝损伤有明显保护作用;对肠管和在位胃运动有抑制作用,显著对抗催产素引起的子宫收缩;能抑制小鼠扭体、嘶叫、热板反应,对吗啡抑制扭体反应有协同作用,并能对抗戊四唑所致惊厥。
甘草:味甘,性平。归胃、肺、脾经。具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药等功效。常用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性等症。本品有解毒、祛痰、止痛、解痉、抗癌、调节机体免疫功能、抗心律失常、降血脂、抗动脉粥样硬化、抑制血小板聚集、抗肿瘤等药理作用。此外,本品还善于解除附子的毒性。
八角枫根:味辛,性温,有毒。具有祛风,通络,散瘀,镇痛,并有麻醉及松弛肌肉等功效。常用于治疗风湿疼痛,麻木瘫痪,心力衰竭,劳伤腰痛,跌打损伤等症。八角枫具有明显的横纹肌松弛作用和一定的镇痛作用;本品的强心作用明显,无异位心律的副作用,能使心率减慢,对风湿病的活动期亦有效,可使风湿病病人的房性过早搏动消失,及I度房室传导阻滞转为正常,同时可使风湿病的临床表现有所改善;抗早孕作用。
本发明的特优点在于:
组成本发明的各中药原料配伍合理、药效协同、固本培元对于间质性膀胱炎的治疗具有疗效明显,无不良反应,成方简单,治疗费用低廉等优点。
具体实施方式:
实施例1:
一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪12份,附子8份,当归10份,苦参5份,白芍10份,甘草5份,八角枫根10份。
实施例2:
一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪8份,附子5份,当归10份,苦参8份,白芍12份,甘草5份,八角枫根8份。
实施例3:
一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪20份,附子10份,当归15份,苦参10份,白芍15份,甘草10份,八角枫根15份。
实施例1-3均采用以下制备与服用方法:
按上述中药配方中重量组份取各种原料,使用传统的中药制备方法,煎煮数次,合并煎煮液,分早中晚三次服用,连服一周为一个疗程。
Claims (2)
1.一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪5-20份,附子2-10份,当归5-15份,苦参5-10份,白芍5-15份,甘草3-10份,八角枫根5-15份。
2.根据权利要求1中所述的一种治疗间质性膀胱炎的中药组合物,其特征在于是由以下重量组份的中药原料制成:黄芪12份,附子3份,当归10份,苦参5份,白芍10份,甘草5份,八角枫根10份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410434817.XA CN104224962A (zh) | 2014-08-30 | 2014-08-30 | 一种治疗间质性膀胱炎的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410434817.XA CN104224962A (zh) | 2014-08-30 | 2014-08-30 | 一种治疗间质性膀胱炎的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104224962A true CN104224962A (zh) | 2014-12-24 |
Family
ID=52214439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410434817.XA Pending CN104224962A (zh) | 2014-08-30 | 2014-08-30 | 一种治疗间质性膀胱炎的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104224962A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055578A (zh) * | 2015-09-06 | 2015-11-18 | 济南知尔医药科技有限公司 | 一种治疗间质性膀胱炎的中药组合物 |
| CN105641463A (zh) * | 2016-04-21 | 2016-06-08 | 王先利 | 一种治疗间质性膀胱炎的中药 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169308A (zh) * | 1996-06-29 | 1998-01-07 | 郭万启 | 一种治疗前列腺增生、前列腺炎及泌尿系结石的中成药 |
| CN1383886A (zh) * | 2002-06-07 | 2002-12-11 | 姚景孝 | 前列腺十八味丸 |
| CN101966278A (zh) * | 2010-09-25 | 2011-02-09 | 安徽省药物研究所 | 一种治疗泌尿道感染的中药及其制备方法 |
| CN103536839A (zh) * | 2013-10-31 | 2014-01-29 | 金占荣 | 一种治疗膀胱炎的药物及其制备方法 |
| CN103768441A (zh) * | 2014-02-28 | 2014-05-07 | 山东省千佛山医院 | 一种治疗膀胱炎的中药组合物 |
-
2014
- 2014-08-30 CN CN201410434817.XA patent/CN104224962A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169308A (zh) * | 1996-06-29 | 1998-01-07 | 郭万启 | 一种治疗前列腺增生、前列腺炎及泌尿系结石的中成药 |
| CN1383886A (zh) * | 2002-06-07 | 2002-12-11 | 姚景孝 | 前列腺十八味丸 |
| CN101966278A (zh) * | 2010-09-25 | 2011-02-09 | 安徽省药物研究所 | 一种治疗泌尿道感染的中药及其制备方法 |
| CN103536839A (zh) * | 2013-10-31 | 2014-01-29 | 金占荣 | 一种治疗膀胱炎的药物及其制备方法 |
| CN103768441A (zh) * | 2014-02-28 | 2014-05-07 | 山东省千佛山医院 | 一种治疗膀胱炎的中药组合物 |
Non-Patent Citations (3)
| Title |
|---|
| 常风云等: "通补兼施治久淋四法", 《河北中医》 * |
| 张丽芬: "黄文政教授治疗慢性尿路感染经验", 《北京中医药大学学报》 * |
| 赵因: "周德安治疗间质性膀胱炎经验", 《中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055578A (zh) * | 2015-09-06 | 2015-11-18 | 济南知尔医药科技有限公司 | 一种治疗间质性膀胱炎的中药组合物 |
| CN105641463A (zh) * | 2016-04-21 | 2016-06-08 | 王先利 | 一种治疗间质性膀胱炎的中药 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105561214A (zh) | 一种治疗冠心病的中药组合物 | |
| CN103191291B (zh) | 一种治疗病毒性心肌炎的中药组合物 | |
| CN103768531B (zh) | 用于治疗类风湿关节炎的中药组合物及其制备方法 | |
| CN103041119B (zh) | 一种治疗心脏病的中药 | |
| CN103877247A (zh) | 用于治疗褥疮的药物及其制备方法 | |
| CN106692669A (zh) | 一种用于治疗斑秃、脱发的中药组合物 | |
| CN102727823B (zh) | 一种用于脑出血术后康复的药物 | |
| CN105343466A (zh) | 一种治疗冠心病的中药组合物 | |
| CN104258304A (zh) | 一种通经祛风活络消痛的药酒 | |
| CN104224962A (zh) | 一种治疗间质性膀胱炎的中药组合物 | |
| CN101554471B (zh) | 治疗心肌梗塞的中药制剂 | |
| CN103977379A (zh) | 一种治疗胆汁反流性胃炎的中药制剂 | |
| CN103920058A (zh) | 一种治疗头痛的中药制剂及其制备方法 | |
| CN103251735A (zh) | 一种治疗阵发性室上性心动过速的中药 | |
| CN103223137B (zh) | 一种降血糖的中药制剂 | |
| CN101987135A (zh) | 一种治疗破伤风的药物及其制备方法 | |
| CN104998074A (zh) | 一种治疗胃病的中药及其制备方法 | |
| CN103182035B (zh) | 用于治疗老年慢性心律失常的中药组合物及其制备方法 | |
| CN104117018A (zh) | 一种治疗冠心病的中药组合物 | |
| CN103463463A (zh) | 一种补血活血、祛风除湿的中药制剂 | |
| CN104740193A (zh) | 一种治疗颈肩肌肉劳损综合症的中药组合物及其制备方法 | |
| CN105232159A (zh) | 一种防治高血压的套盒 | |
| CN105709176A (zh) | 一种治疗心血瘀阻型心悸的中药组合物及其制备方法 | |
| CN103083552B (zh) | 一种用于治疗神经性皮肤炎症的药丸 | |
| CN101310755A (zh) | 一种促进骨折快速痊愈的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141224 |